Your Article Summary
See Latest ArticlesRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09
Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in pts with type 2 diabetes is confirmed to increase risk of heart failure and of some fractures, mainly in women. Despite inconclusive data are about any possible effect on myocardial infarction, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.
Methods- Study of cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea vs combination over 5—7 yr follow-up
- Assessment of comparative safety
- Multicentre, open-label trial of 4447 pts with type 2 diabetes on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
- Randomization to addition of rosiglitazone (n=2220) or combination of metformin and sulfonylurea (active control group, n=2227)
- Primary endpoint: cardiovascular hospitalization or cardiovascular death
- 321 pts in rosiglitazone group and 323 in active control group experienced primary outcome during mean 5.5-yr follow-up, meeting criterion of non-inferiority
- HR was 0.84 for cardiovascular death, 1.14 for myocardial infarction, and 0.72 for stroke
- Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
- Upper and distal lower limb fracture rates increased mainly in women assigned to rosiglitazone
- Mean HbA1c lower in rosiglitazone vs control group at 5 yrs
Related Articles
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09
Relevance Score: 88%
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09
Relevance Score: 87%
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 87%
Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09
Relevance Score: 85%
Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09
Relevance Score: 85%
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Circulating vaspin is unrelated to insulin sensitivity in a cohort of non-diabetic humans
European Journal of Endocrinology, 12/14/09
Plasma Total Homocysteine Levels and Methylenetetrahydrofolate Reductase Gene Polymorphism in Patients with Type 2 Diabetes Mellitus
Pathophysiology of Haemostasis and Thrombosis, 12/14/09
Comparison of antihyperglycemic effects of creatine and metformin in type II diabetic patients
Clinical and Investigative Medicine, 12/14/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/14/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/14/09
The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs
Current Opinion in Lipidology, 12/14/09
Today in Coronary Artery Disease...keeping you current
Receive free subspecialty "5-minute updates" via email
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events
European Heart Journal, 12/14/09
Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries
Current Opinion in Lipidology, 12/14/09
Personalized antiplatelet therapy for coronary artery disease patients: is this the future?
Expert Review of Cardiovascular Therapy , 12/14/09
Today in Cardiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events
European Heart Journal, 12/14/09
Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction
European Heart Journal, 12/14/09
Hypertension Prevalence and Prescribing Trends in Older US Adults: 1999-2004
The Journal of Clinical Hypertension, 12/14/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Milnacipran: Beyond a Role of Antidepressant
Clinical Neuropharmacology, 12/14/09
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/14/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/14/09
Today in Vascular Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs
Current Opinion in Lipidology, 12/14/09
Travel-related thromboembolism: mechanisms and avoidance
Expert Review of Cardiovascular Therapy , 12/14/09
High-throughput ambulatory assessment of digital reactive hyperemia: Concurrent validity with known cardiovascular risk factors and potential confounding
Preventive Medicine, 12/14/09